| Literature DB >> 29262796 |
Ke Zheng1, Haiyun Wang1, Bo Hou2, Hui You2, Jing Yuan3, Kai Luo4, Limeng Chen1, Mingxi Li1, Qun Xu4, Yicheng Zhu3, Liying Cui3, Sagar Uday Nigwekar5, Feng Feng2, Xuemei Li6.
Abstract
BACKGROUND: Chronic kidney disease patients have an increased prevalence of subclinical cerebrovascular diseases. Dialysis patients have severe vascular diseases burden. The cerebral small vessel diseases (CSVD) are difficult to find by clinical assessment. The evaluation of CVSD needs MRI. Cognitive impairment is a consequence of CVSD which is diagnosed by cognitive testing. These limited the study of CVSD and cognitive function in dialysis patients. Peritoneal dialysis (PD) patients are minority of dialysis population. We know even fewer about the CVSD in this special population.Entities:
Keywords: Cerebral small vessel disease; Cognitive function; Inflammation; Malnutrition; Peritoneal dialysis
Mesh:
Year: 2017 PMID: 29262796 PMCID: PMC5738894 DOI: 10.1186/s12882-017-0777-1
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow chart of Patient enrollment. 196 PD patients were screened, and eventually 72 patients were enrolled. All of the enrolled patients received MRI and 67 of them finished cognitive tests
Demographic information and clinical features (n = 72) (mean ± sd)
| Demographic information and clinical history | |
| Age (yr) | 56.2 ± 16.0 |
| Male (%) | 37.5 |
| Smoker (%) | 16.7 |
| Dialysis vintage (m) | 41.2 ± 36.1 |
| BMI (kg/m2) | 22.9 ± 3.6 |
| Average blood pressure (mmHg) | 137.8/77.2 ± 21.6/13.6 |
| Hypertension (%) | 90.3 |
| Hypertension duration (m, median (range)) | 95.8 (1.53–658.3); |
| Diabetes mellitus (%) | 31.9 |
| DM duration (m, median (range)) | 165.0 (48.3–462.5) |
| Atherosclerosis (%) | 18.1 |
| Atherosclerosis duration (m, median (range)) | 79.1 (4.2–164.2) |
| History of ischemia stroke (%) | 5.6 |
| History of hemorrhagic stroke (%) | 1.4 |
| Undergoing antiplatelet therapy1(%) | 29.2 |
| Patients on ACEI (%) | 13.9 |
| Patients on ARB (%) | 36.1 |
| Dialysis and laboratory evaluation | |
| Hemoglobin (g/L) | 113.9 ± 13.7 |
| Serum albumin (g/L) | 35.4 ± 3.9 |
| Serum creatinine (umol/L) | 858.3 ± 271.1 |
| Urea nitrogen (mmol/L) | 18.0 ± 5.2 |
| Serum uric acid (umol/L) | 369.2 ± 60.0 |
| Calcium and phosphamid product (mmol2/L2) | 3.6 ± 1.0 |
| Serum TCHO (mmol/L) | 4.6 ± 1.0 |
| Serum TG (mmol/L) | 1.9 ± 1.2 |
| hs CRP (mg/L) | 6.4 ± 8.9 |
| TSAT (%) | 29.1 ± 12.0 |
| iPTH (pg/ml) | 359.7 ± 475.1 |
| β2-MG (mg/L) ( | 35.7 ± 14.1 |
| Weekly total KT/Vureaa | 2.2 ± 0.7 |
| nPCR (g/kg/d)b | 0.9 ± 0.25 |
a total weekly Kt/Vurea(L/1.73 m2) = (Daily PD Kt/Vurea + (Daily RR Kt/Vurea) × 7 days. Daily PD Kt/Vurea = [dialysate urea concentration × 24-h peritoneal drain volume (L)/plasma urea concentrations]/ Vurea. Daily residual renal Kt Vurea = [Urine urea × 24-h urine volume (L)]/plasma urea concentrations]/ Vurea. Vurea: Adult male = 2.774–0.09516 x age (yr) + 0.1074 x Height (cm) + 0.3362 x weight (kg). Adult female = −0.2097 + 0.1069 x Height (cm) + 0.2466 x weight (kg)
bnPCR = 10.76[(Vd(L) xDUN(mmol/L) + Vu(L) xUUN(mmol/L))*14*2/1440(min) +1.46]/body weight. Vd, 24-h peritoneal drain volume; DUN, the urea concentration in the pooled drained dialysate: Vu, 24-h urine volume; UUN, the urea concentration in the urine.
1antiplatelet therapy including asprine and/or clopidogrel
Fig. 2Typical images of different signs of CSVDs in PD patients. a Lacunar infarct, Insular subcortical, T2WI images; b Abnormal white matter hyperintensities, bilateral periventricular, T2-FLAIR images; c Microbleeds, bilateral parietal lobe white matter, SWI images; d Hematoma, bilateral basal ganglia and dorsal thalamus, SWI images
Associations between nPCR/hsCRP and different kinds of CSVDa
| Model | Intracerebral hemorrhage | lacunar infarcts | Abnormal WMH | Microbleeds | ||||
|---|---|---|---|---|---|---|---|---|
| nPCRb | hsCRPc | nPCR | hsCRP | nPCR | hsCRP | nPCR | hsCRP | |
| Model 1d |
| 1.51 (0.62, 3.64) |
|
| 0.93 (0.79, 1.11) |
| 0.96 (0.81,1.15) | 1.39 (0.98,1.99) |
| Model 2e |
| 1.58 (0.58, 4.32) |
| 1.29 (0.85, 1.97) | 1.02 (0.79, 1.31) | 0.91 (0.55, 1.52) | 0.98 (0.82,1.18) |
|
| Model 3f |
| 2.07 (0.68, 6.26) |
| 1.23 (0.78, 1.92) | 0.98 (0.76, 1.27) | 0.92 (0.55, 1.55) | 0.95 (0.78,1.15) | 1.48 (0.95,2.30) |
| Model 4g | 1.12 (0.45, 2.81) |
|
| 0.70 (0.35, 1.38) | 1.07 (0.78, 1.47) | 0.95 (0.52, 1.73) | 0.95 (0.77,1.19) | 1.29 (0.80,2.10) |
aestimates were based on logistic regression; bthe unit of change is per log(nPCR)/10(g/kg/d); cthe unit of change is per log(hsCRP)(mg/L). donly with nPCR/hsCRP; eadjusted for age and gender; fadditionally adjusted diabetes and smoking status; gadditionally adjusted diabetes, smoking and significant variables in univariate analysis (for Intracerebral hemorrhage: BMI and nPCR; for lacunar infarcts; hsCRP, nPCR, TSAT, Scr, BUN and Alb; for abnormal WMH::hsCRP, Alb, diastolic blood pressure. ARB and antiplatelet medication for microbleeds: hsCRP, TSAT, antiplatelet medication). hdid not adjust for nPCR because of an abnormal coefficient. *p<0.05
Associations between nPCR/hsCRP and MMSE/MoCAa
| MMSE | MoCA | |||||||
|---|---|---|---|---|---|---|---|---|
| nPCRb | hsCRPc | nPCR | hsCRP | |||||
| Model | Coefficient (95%CI) |
| Coefficient (95%CI) |
| Coefficient (95%CI) |
| Coefficient (95%CI) |
|
| Model1d | 0.15 (0.04, 0.25) |
| −0.03 (−0.05, 0.01) |
| 0.40 (0.13, 0.68) |
| −0.07 (−0.12, −0.02) |
|
| Model2e | 0.13 (0.03, 0.23) |
| −0.02 (−0.04, 0.01) | 0.1509 | 0.36 (0.12, 0.59) |
| −0.02 (−0.07, 0.04) | 0.5319 |
| Model3f | 0.14 (0.03, 0.24) |
| −0.02 (−0.04, 0.01) | 0.1552 | 0.36 (0.12, 0.60) |
| −0.02 (−0.07, 0.04) | 0.5765 |
| Model4g | 0.08 (−0.04, 0.18) | 0.2109 | 0.01 (−0.02, 0.03) | 0.5148 | 0.30 (0.03, 0.57) |
| 0.05 (−0.01, 0.10) | 0.1137 |
aestimates were based on general linear regression; bthe unit of change is per log(npcr) (g/kg/d); cthe unit of change is per log(hscrp)(mg/L). donly with nPCR/hsCRP; eadditionally adjusted for age and gender;. fadditionally adjusted for diabetes and smoking status;. gadditionally adjusted significant variables in univariate analysis(Additional file 1: Table S2) (for MMSE, BUN, TG and hsCRP/nPCR; for MoCA, usage of ACEi, SCr, BUN, TG and hsCRP/nPCR) *p < 0.05
The influence of different CSVD signs on cognitive function
| MMSE(log) | MoCA(log) | ||||
|---|---|---|---|---|---|
| Mean ± SD |
| Mean ± SD |
| ||
| Univariate analyses | |||||
| lacunar infarct | 0 ( | 3.35 ± 0.073 |
| 3.16 ± 0.20 |
|
| 1 ( | 3.25 ± 0.16 | 2.86 ± 0.38 | |||
| Microbleed | 0 ( | 3.33 ± 0.13 | 0.1186 | 3.07 ± 0.32 | 0.1727 |
| 1 ( | 3.28 ± 0.12 | 2.96 ± 0.33 | |||
| chronic intracerebral hemorrhage | 0 ( | 3.31 ± 0.13 | 0.5324 | 3.04 ± 0.32 | 0.2300 |
| 1 ( | 3.27 ± 0.12 | 2.81 ± 0.43 | |||
| Abnormal WMH | 0 ( | 3.34 ± 0.09 |
| 3.13 ± 0.29 |
|
| 1 ( | 3.28 ± 0.15 | 2.93 ± 0.33 | |||
| Multivariate analyses | |||||
| lacunar infarct | 0 | 3.36 ± 0.04 |
| 3.15 ± 0.10 |
|
| 1 | 3.26 ± 0.04 | 2.84 ± 0.10 | |||
| Microbleed | 0 | 3.31 ± 0.04 | 0.9904 | 2.97 ± 0.10 | 0.5463 |
| 1 | 3.31 ± 0.04 | 3.02 ± 0.10 | |||
| chronic intracerebral hemorrhage | 0 | 3.29 ± 0.02 | 0.7728 | 3.01 ± 0.10 | 0.5852 |
| 1 | 3.32 ± 0.07 | 2.97 ± 0.09 | |||
| Abnormal WMH | 0 | 3.32 ± 0.04 | 0.7297 | 2.97 ± 0.09 | 0.5443 |
| 1 | 3.30 ± 0.04 | 3.02 ± 0.10 | |||
*p < 0.05